Hydroxyurea and didanosine long-term treatment prevents HIV breakthrough and normalizes immune parameters

F. Lori, E. Rosenberg, J. Lieberman, A. Foli, R. Maserati, E. Seminari, F. Alberici, B. Walker, J. Lisziewicz

Research output: Contribution to journalArticlepeer-review

Abstract

Hydroxyurea and didanosine treatment suppressed HIV replication for more than 2 years, in the absence of viral breakthrough, in chronically infected patients. The profile of viral load reduction was unusual for a two-drug combination, since a continuous gradual decrease in viremia persisted despite residual viral replication. The increase in CD4+ T cell counts was not robust. However, unlike those of patients treated by other therapies, CD4+ T lymphocytes were functionally competent against HIV, mediating a vigorous HIV-specific helper T cell response in half of these patients. In addition, the percentages of naive CD4+ and CD8+ T lymphocytes were not different from those in uninfected individuals. These results demonstrate that prolonged antiretroviral therapy with a simple, well-tolerated combination of two affordable drugs can lead to sustained control of HIV, normalization of immune parameters, and specific anti-HIV immune response.

Original languageEnglish
Pages (from-to)1333-1338
Number of pages6
JournalAIDS Research and Human Retroviruses
Volume15
Issue number15
DOIs
Publication statusPublished - Oct 10 1999

ASJC Scopus subject areas

  • Immunology
  • Virology

Fingerprint Dive into the research topics of 'Hydroxyurea and didanosine long-term treatment prevents HIV breakthrough and normalizes immune parameters'. Together they form a unique fingerprint.

Cite this